Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
What This Evernorth GLP-1 Coverage Downtick Means for the Broader Market Cignas experience reflects a broader affordability challenge facing employers nationwide as GLP-1 drugs for weight management remain expensive despite growing patient demand
Slow titration is the single biggest lever for tolerability
Glass vials protect peptides from external factors like light and air, preserving their potency and efficacy over time
A 17% Reduction in Overall Cancer Risk A landmark study published in JAMA Oncology (Dai H et al., August 2025), drawing on data from 14 health systems encompassing approximately 20 million patients, found that adults with obesity who were prescribed GLP-1 receptor agonists had a 17% lower risk of developing cancer compared to carefully matched non-users
